Gina Bartasi, the CEO and founder of the New York-based fertility chain Kindbody, is stepping down from her role. In a move reflecting the company's changing leadership and ongoing financial challenges, the firm announced Bartasi's departure, stating she will transition out of the startup "over the next couple of months." This information comes directly from Bloomberg, and is detailed on Kindbody's own website.
Following the CEO's departure, Kindbody is setting up a newly minted "office of the CEO," which will include President Gina Bruzzichesi, Chief Financial Officer Scott Bruckner, and Chief Business Officer Shilpa Patel. They will collectively manage operations, ensuring continuity of leadership. In addition, board member Linda Mintz is stepping into the role of chairperson amid these strategic shifts, as reported by Crain's New York.
The challenge facing Kindbody is multi-faceted; the company has witnessed a significant downturn in valuation, dropping from its peak of $1.8 billion in 2023. It emerged from a Bloomberg report that Kindbody is both exploring a potential sale and seeking $10 million in bridge financing to maintain operations. This comes after a failed effort to secure a funding round aimed to raise between $30 million and $50 million, amid investor concerns revolving around the company's financial health.
This is not the first time Bartasi has altered her grip on the company's reins. She initially stepped back following the acquisition of Vios Fertility Institute in 2022, but resumed the role the following year after a successor was not secured, as indicated in a text message obtained by Bloomberg. The company's operational challenges have been further compounded by multiple clinic closures this year, leading to a downward revision of its revenue forecast and a scramble to shore up funding against what it has described to investors as significant cash depletion.
As the company navigates these challenges, the details of Bartasi's future involvement and the extent of the impact from its recent issues remain uncertain. Kindbody, one of the largest fertility chains in the U.S., offering services such as in-vitro fertilization and egg freezing, now faces the task of addressing investor confidence and client trust amid leadership changes and ongoing financial and ethical scrutiny.
